Latest news with #ShareOptionPlan
Hamilton Spectator
27-05-2025
- Business
- Hamilton Spectator
Grant of Performance Share Awards Under Long Term Incentive Plan and PDMR Shareholdings
VANCOUVER, British Columbia, May 27, 2025 (GLOBE NEWSWIRE) — Cornish Metals Inc. (AIM/TSX-V: CUSN) ('Cornish Metals' or the 'Company'), a mineral exploration and development company focused on advancing its 100% owned and permitted South Crofty tin project in Cornwall, United Kingdom, announces that on 23 May 2025, the Company granted conditional performance share awards ('Performance Awards') under the new Cornish Metals Long Term Incentive Plan ('LTIP') which was approved by shareholders on 18 March 2025. Performance Awards have been granted over a total of up to 12,837,423 common shares of the Company to certain employees pursuant to the LTIP. In determining the number of awards, the Company has used a share price of 8.15p, being the closing price on 22 May 2025. The LTIP awards will vest on 31 December 2027, subject to meeting certain strategic, operational, financial and shareholder return performance criteria and the continued employment of the participant. The targets are in relation to the following performance conditions: Following these grants there are 12,837,423 unvested Performance Awards under the Company's LTIP, equating to approximately 1.03% of the issued share capital of the Company. There are also 25,916,667 share options under the legacy Share Option Plan, equating to approximately 2.07% of the issued share capital of the Company. No further awards under the legacy Share Option Plan will be made. PDMR Grants Don Turvey, Matthew Hird and Fawzi Hanano have been granted the following Performance Awards: The notification below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail. ABOUT CORNISH METALS Cornish Metals is a dual-listed mineral exploration and development company (AIM and TSX-V: CUSN) that is advancing the South Crofty tin project towards production. South Crofty: ON BEHALF OF THE BOARD OF DIRECTORS 'Don Turvey' Don Turvey CEO and Director Engage with us directly at our investor hub. Sign up at: For additional information please contact: Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release . Caution regarding forward looking statements This news release may contain certain 'forward-looking information' and 'forward-looking statements' (collectively, 'forward-looking statements'). Forward-looking statements include predictions, projections, outlook, guidance, estimates and forecasts and other statements regarding future plans, the realisation, cost, timing and extent of mineral resource or mineral reserve estimates, estimation of commodity prices, currency exchange rate fluctuations, estimated future exploration expenditures, costs and timing of the development of new deposits, success of exploration activities, permitting time lines, requirements for additional capital and the Company's ability to obtain financing when required and on terms acceptable to the Company, future or estimated mine life and other activities or achievements of Cornish Metals. Forward-looking statements are often, but not always, identified by the use of words such as 'seek', 'anticipate', 'believe', 'plan', 'estimate', 'forecast', 'expect', 'potential', 'project', 'target', 'schedule', 'budget' and 'intend' and statements that an event or result 'may', 'will', 'should', 'could', 'would' or 'might' occur or be achieved and other similar expressions and includes the negatives thereof. All statements other than statements of historical fact included in this news release, are forward-looking statements that involve various risks and uncertainties and there can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are subject to risks and uncertainties that may cause actual results to be materially different from those expressed or implied by such forward-looking statements, including but not limited to: risks related to receipt of regulatory approvals, risks related to general economic and market conditions; risks related to the availability of financing; the timing and content of upcoming work programmes; actual results of proposed exploration activities; possible variations in Mineral Resources or grade; projected dates to commence mining operations; failure of plant, equipment or processes to operate as anticipated; accidents, labour disputes, title disputes, claims and limitations on insurance coverage and other risks of the mining industry; changes in national and local government regulation of mining operations, tax rules and regulations. The list is not exhaustive of the factors that may affect Cornish's forward-looking statements. Cornish Metals' forward-looking statements are based on the opinions and estimates of management and reflect their current expectations regarding future events and operating performance and speak only as of the date such statements are made. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ from those described in forward- looking statements, there may be other factors that cause such actions, events or results to differ materially from those anticipated. There can be no assurance that forward-looking statements will prove to be accurate and accordingly readers are cautioned not to place undue reliance on forward-looking statements. Cornish Metals does not assume any obligation to update forward-looking statements if circumstances or management's beliefs, expectations or opinions should change other than as required by applicable law.
Yahoo
23-05-2025
- Business
- Yahoo
NORTHCLIFF REPORTS ANNUAL GENERAL MEETING RESULTS
VANCOUVER, BC, May 23, 2025 /CNW/ - Northcliff Resources Ltd. ("Northcliff" or the "Company") (TSX: NCF) announces the voting results from its 2025 Annual General Meeting held on May 22, 2025 in Vancouver, British Columbia (the "Meeting'). A total of 499,973,223 common shares were voted at the Meeting, representing 82.37% of the votes attached to all outstanding common shares. Shareholders voted in favour of all items of business before the Meeting, except the continuation of the Company's Share Option Plan. The votes for the election of director nominees were as follows: DIRECTOR % of Votes in Favor Andrew Ing 99.98 % Peter C. Mitchell 99.97 % T. Barry Coughlan 99.98 % Scott. D. Cousens 99.98 % Michael Wolley 99.91 % Detailed voting results for the Meeting are available at the Company's profile on SEDARplus at About Northcliff Resources Ltd. Northcliff is a mineral resource company focused on advancing the feasibility-stage Sisson Tungsten-Molybdenum Project located in New Brunswick, Canada, to production. Additional information on Northcliff is available on the website at Investor services can be reached at (604) 684-6365 or within North America at 1-800-667-2114. Andrew IngChairman, CEO SOURCE Northcliff Resources Ltd. View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14-05-2025
- Business
- Yahoo
Faron Pharmaceuticals Ltd: Grant of Options
TURKU, FINLAND / / May 14, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN): Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, todayannounces that the Company's board has confirmed the grant of a total of 876,000options over ordinary shares in the Company ("Options") under the Company's Share Option Plan 2019 (including its UK and US sub plans). The Options have been allocated under the Share Option Plan 2019 and are exercisable between April 4, 2026 and April 4, 2031, vesting 25% per annum over four years. The exercise price for Options allocated under the Share Option plan is €2.20 per share, which is calculated based on the average price per share at which the ordinary shares in the Company have been traded on AIM for 90 days preceding the allocation date of 4 April 2025. The exercise price for Options allocated under the US sub plan is €2.31 per share, which is calculated based on the average price per share at which the ordinary shares in the Company have been traded on AIM for 30 days preceding the allocation date of 4 April 2025. The terms of the Share Option Plan 2019 are available on the Company's website at The granted 876,000 Options entitle the option holders to subscribe for a total of 876,000new ordinary shares in the Company, if exercised in full, and represent 0.78 %of the fully diluted ordinary share capital of the Company. Included in the number of Options granted are the following Options which were issued to directors, other persons discharging managerial responsibilities ("PDMRs") and Company personnel: Director Options granted Colin Bond 30,000 Marie-Louise Fjällskog 30,000 Juho Jalkanen 200,000 Markku Jalkanen 30,000 John Poulos 30,000 Tuomo Tuomo Pätsi 100,000 Christine Roth 30,000 Total directors 450,000 Other PDMR Maija Hollmén 6,000 Vesa Karvonen 30,000 Yrjö Wichmann 60,000 Kaisa Kyttä 11,000 Petri Bono 30,000 Total other PDMRs 137,000 Total Company personnel 876,000 For more information, please contact: IR Partners, Finland(Media)Riina TuominenKare Laukkanen +358 44 313 50 553 9535 / +44 7 469 766 FINN Partners, US(Media) Alyssa Paldo +1 847 791-8085 Cairn Financial Advisers LLP(Nominated Adviser and Broker)Sandy Jamieson, Jo Turner +44 (0) 207 213 0880 Sisu Partners Oy(Certified Adviser on Nasdaq First North)Juha KarttunenJukka Järvelä +358 (0)40 555 4727+358 (0)50 553 8990 About BEXMABThe BEXMAB study is an open-label Phase I/II clinical trial investigating bexmarilimab in combination with standard of care (SoC) in the aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The primary objective is to determine the safety and tolerability of bexmarilimab in combination with SoC (azacitidine) treatment. Directly targeting Clever-1 could limit the replication capacity of cancer cells, increase antigen presentation, ignite an immune response, and allow current treatments to be more effective. Clever-1 is highly expressed in both AML and MDS and associated with therapy resistance, limited T cell activation and poor outcomes. About Bexmarilimab Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care. About Faron Pharmaceuticals Ltd. Faron (AIM:FARN)(First North:FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 1 Details of the person discharging managerial responsibilities/person closely associated a. Name a) Colin Bondb) Marie-Louise Fjällskogc) Juho Jalkanend) Markku Jalkanene) John Poulosf) Tuomo Pätsig) Christine Rothh) Maija Hollméni) Vesa Karvonenj) Yrjö Wichmannk) Kaisa Kyttäl) Petri Bono 2 Reason for notificationa. Position/Status Person discharging managerial responsibilities/person closely associated b. Initial notification/Amendment Initial notification 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a. Name Faron Pharmaceuticals Oy b. LEI 7437009H31TO1DC0EB42 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a. Description of the financial instrument, type of instrumentIdentification Code Options over new ordinary sharesISIN: FI4000153309 b. Nature of the transaction Grant of options made under the Faron Share Option Plan 2019 - under the UK and US sub plans the options are exercisable at €2.20 per ordinary share, and at €2.31 per ordinary share respectively. c. Price(s) and volume(s)Price(s) Volume(s) a) €2.20b) €2.31c) €2.20d) €2.20e) €2.31f) €2.20g) €2.31h) €2.20i) €2.20j) €2.20k) €2.20l) €2.20 a) 30,000b) 30,000c) 200,000d) 30,000e) 30,000f) 100,000g) 30,000h) 6,000i) 30,000j) 60,000k) 11,000l) 30,000 d. Aggregated information- Aggregated Volume- Price Nil e. Date of the transaction 14 May 2025 f. Place of the transaction Turku SOURCE: Faron Pharmaceuticals View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
02-04-2025
- Business
- Yahoo
Organto Foods Announces Increase to Private Placement Financing
VANCOUVER, BC AND BREDA, THE NETHERLANDS / / April 1, 2025 / Organto Foods Inc. (TSX-V:OGO)(OTC PINK:OGOFF) ("Organto" or the "Company") today announced its plan to increase the size of its recently announced non brokered private placement (see news release dated March 20, 2025) from C$5,000,000 to up to $5,500,000 (the "Private Placement"). Private Placement The Company now proposes to conduct a non-brokered private placement of up to 55,000,000 common shares of the Company at the price of $0.10 per share for gross proceeds of up to C$5,500,000. When combined with other ongoing debt restructuring activities, the Company expects to have approximately 155,000,000 shares outstanding once completed. The Company may pay finders' fees on the gross proceeds raised through the Private Placement in cash or shares or a combination thereof. The net proceeds from the Private Placement will be used for repayment of short-term loans and to fund general working capital. Certain directors and officers of the Company may acquire securities under the Private Placement. Any such participation would be considered to be a "related party transaction" as defined under Multilateral Instrument 61-101 ("MI 61-101"). The transaction will be exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of any shares issued to, or the consideration paid by such persons will exceed 25% of the Company's market capitalization. Completion of the Private Placement will be subject to the prior approval of the TSX Venture Exchange as well as all other requisite corporate, regulatory and security holder approvals, as applicable. Further, all securities issued pursuant to the Private Placement will be subject to a minimum hold period of four months and one day from their date of issuance. Grant of Stock Options and Restricted Share Units The Company also announces that it has granted a total of 1,300,000 stock options to certain officers and directors as per the terms of the Company's Share Option Plan. The options were granted at an exercise price of $0.12 per share and have a term of five years. 700,000 options will vest 20% immediately and 20% on each anniversary thereafter while 600,000 options will vest 25% immediately and 25% every six months thereafter. In addition, 150,000 restricted stock units were issued to certain directors of the Company as per the terms of the Company's Restricted Share Unit Plan. The restricted share units have a term of 3 years and will vest one-third after one-year and one-third every six months thereafter. ON BEHALF OF THE BOARD Steve BromleyChairman and CEO For more information, contact: Investor RelationsJohn Rathwell, Senior Vice President, Investor Relations & Corporate Development647 629 0018info@ ABOUT ORGANTO Organto is a leading provider of branded, private label, and distributed organic and non-GMO fruit and vegetable products using a strategic asset-lighter business model to serve a growing socially responsible and health-conscious consumers. Organto's business model is rooted in its commitment to sustainable business practices focused on environmental responsibility and a commitment to the communities where it operates, its people, and its shareholders. FORWARD LOOKING STATEMENTS This news release may include certain forward-looking information and statements, as defined by law, including without limitation, Canadian securities laws and the "safe harbor" provisions of the US Private Securities Litigation Reform Act ("forward-looking statements"). In particular, and without limitation, this news release contains forward-looking statements respecting the Company's proposed private placement and debt restructuring activities. Forward-looking statements are based on a number of assumptions that may prove to be incorrect, including, without limitation, the assumption that the Company will be able to complete its planned private placement and debt restructuring activities in a timely manner. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in forward-looking statements in this news release include, among others, uncertainty regarding the outcome of negotiations with the Company's creditors; regulatory risks; risks related to market volatility and economic conditions; risks related to unforeseen delays; and risks that necessary financing will be unavailable when needed. For further information on these and other risks and uncertainties that may affect the Company's business, see the "Risks and Uncertainties" and "Forward-Looking Statements" sections of the Company's annual and interim management's discussion and analysis filings with the Canadian securities regulators, which are available under the Company's profile at Except as required by law, Organto does not assume any obligation to release publicly any revisions to forward-looking statements contained in this news release to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. SOURCE: Organto Foods, Inc. View the original press release on ACCESS Newswire Sign in to access your portfolio
Globe and Mail
31-03-2025
- Business
- Globe and Mail
LSL PHARMA GROUP APPOINTS LOUIS LAFLAMME TO THE BOARD OF DIRECTORS
BOUCHERVILLE, QC , March 31, 2025 /CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL) (TSXV: (the "Corporation" or "LSL Pharma"), a Canadian integrated pharmaceutical company, is pleased to announce the appointment of Louis Laflamme as a member of the board of directors. "We are delighted to see Louis, a renowned leader in the health industry, join our board of directors. Louis has had success in building OpSens Inc., a revolutionary company in interventional cardiology. His experience with a publicly traded leading global business will be a precious asset for LSL Pharma," said François Roberge, President and CEO. "I am excited to be joining the board of directors of LSL Pharma at such a dynamic phase of the Corporation's growth and evolution. LSL is well positioned to drive adoption in its existing markets for existing revenue lines, while aiming to secure its first U.S. FDA regulatory approval for its sterile ophthalmic products to further capitalize on the U.S. market," said Mr. Laflamme. "I am looking forward to working with the board and management to accelerate and optimize the market opportunities for our products and in doing so, to unlock significant value for our shareholders," he added. Mr. Louis Laflamme is Entrepreneur in Residence for Medtech Ventures Fund of Sectoral Asset Management Inc. Previously, he was President, CEO and director of OpSens Inc. (TSX:OPS) from January 2013 to March 2024 , when it was acquired by Haemonetics for $345 million . During this period, the company revolutionized certain practices in interventional cardiology with medical instruments. From November 2005 to December 2012 , he served as Chief Financial Officer and Corporate Secretary of OpSens. He also serves on the board of directors of SiliCycle, MY01 Inc., Icentia and EMKA SCIREQ Inc. He also held leadership positions in other technology companies. Mr. Laflamme is a member of the Order of Chartered Professional Accountants of Quebec . He holds a Bachelor's degree in Business Administration from Laval University . In connection with Mr. Laflamme's appointment, the Corporation has granted 500,000 share options to Mr. Laflamme in accordance with its Share Option Plan, subject to regulatory approval. The options vest over three years, are issued at an exercise price of $0.37 cents per Class A share and expire ten (10) years from their date of issuance. Upon completion of this grant, a total of 9,030,270 options will have been granted under the plan, representing 7.8% of the Corporation's outstanding Class A shares. The Corporation also announced that it has entered into an agreement with Mr. Laflamme for advisory and consulting services (the " Services Agreement"). Accordingly, Mr. Laflamme will not be considered as an "independent" director of the Corporation, as defined by applicable securities terms and conditions of the Services Agreement were reviewed and recommended for approval by the Corporation's Governance and Compensation Committee, and the independent members of the Board unanimously approved the Services Agreement. ABOUT LSL PHARMA GROUP INC. LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company specializing in the development, manufacturing, and commercialization of high-quality sterile ophthalmic pharmaceuticals, as well as cosmetics products, pharmaceutical products and natural health products in solid, semi-solid and liquid dosage forms. For further information, please visit
